Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Chapeau EA, Gembarska A, Durand EY, Mandon E, Estadieu C, Romanet V, Wiesmann M, Tiedt R, Lehar J, de Weck A, Rad R, Barys L, Jeay S, Ferretti S, Kauffmann A, Sutter E, Grevot A, Moulin P, Murakami M, Sellers WR, Hofmann F, Jensen MR.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3151-3156. doi: 10.1073/pnas.1620262114. Epub 2017 Mar 6.

2.

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Esfandiari A, Hawthorne TA, Nakjang S, Lunec J.

Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1.

3.

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.

Hoffman-Luca CG, Yang CY, Lu J, Ziazadeh D, McEachern D, Debussche L, Wang S.

PLoS One. 2015 Jun 12;10(6):e0128807. doi: 10.1371/journal.pone.0128807. eCollection 2015.

4.

The role of p53 in cancer drug resistance and targeted chemotherapy.

Hientz K, Mohr A, Bhakta-Guha D, Efferth T.

Oncotarget. 2017 Jan 31;8(5):8921-8946. doi: 10.18632/oncotarget.13475. Review.

5.

Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.

Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I.

Cancer Sci. 2019 Feb;110(2):639-649. doi: 10.1111/cas.13893. Epub 2019 Jan 16.

6.

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.

Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M.

Cancer Res. 2018 May 15;78(10):2721-2731. doi: 10.1158/0008-5472.CAN-17-0949. Epub 2018 Feb 28.

7.

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.

Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T.

Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175.

8.

The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.

Volk EL, Fan L, Schuster K, Rehg JE, Harris LC.

Mol Cancer Res. 2009 Jun;7(6):863-9. doi: 10.1158/1541-7786.MCR-08-0418. Epub 2009 Jun 2.

9.

The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Eischen CM, Lozano G.

Hum Mutat. 2014 Jun;35(6):728-37. doi: 10.1002/humu.22524. Epub 2014 Mar 6. Review.

10.
11.

Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.

Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner LM, Hess EM, Zapatka M, Theißen J, Fischer M, Ehemann V, Schwab M, Savelyeva L, Westermann F.

Hum Mol Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23.

PMID:
23343716
12.

Mouse models of Mdm2 and Mdm4 and their clinical implications.

Xiong S.

Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Review.

13.

Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.

Suda T, Yoshihara M, Nakamura Y, Sekiguchi H, Godai TI, Sugano N, Tsuchida K, Shiozawa M, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Matsukuma S, Miyagi Y.

Oncol Rep. 2011 Jul;26(1):49-54. doi: 10.3892/or.2011.1270. Epub 2011 Apr 18.

PMID:
21503588
14.

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A.

Clin Cancer Res. 2016 Mar 1;22(5):1185-96. doi: 10.1158/1078-0432.CCR-15-1015. Epub 2015 Oct 19. Erratum in: Clin Cancer Res. 2016 May 1;22(9):2313.

15.

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.

Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, Jackson J, Bennaceur K, Xu Q, Makimanejavali AR, Del Bello F, Piergentili A, Newell DR, Hardcastle IR, Griffin RJ, Lunec J.

Oncotarget. 2016 Jul 19;7(29):46203-46218. doi: 10.18632/oncotarget.10073.

16.

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.

Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.

17.

MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Toledo F, Wahl GM.

Int J Biochem Cell Biol. 2007;39(7-8):1476-82. Epub 2007 Apr 8. Review.

18.

Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.

Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J, Silver A.

Int J Cancer. 2007 Dec 15;121(12):2668-73.

19.

Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.

Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL.

Mol Cell Biol. 2001 Nov;21(22):7653-62.

20.

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

Supplemental Content

Support Center